Show simple item record

dc.contributor.authorGhidini, M
dc.contributor.authorCascione, L
dc.contributor.authorCarotenuto, P
dc.contributor.authorLampis, A
dc.contributor.authorTrevisani, F
dc.contributor.authorPrevidi, MC
dc.contributor.authorHahne, JC
dc.contributor.authorSaid-Huntingford, I
dc.contributor.authorRaj, M
dc.contributor.authorZerbi, A
dc.contributor.authorMescoli, C
dc.contributor.authorCillo, U
dc.contributor.authorRugge, M
dc.contributor.authorRoncalli, M
dc.contributor.authorTorzilli, G
dc.contributor.authorRimassa, L
dc.contributor.authorSantoro, A
dc.contributor.authorValeri, N
dc.contributor.authorFassan, M
dc.contributor.authorBraconi, C
dc.date.accessioned2017-10-24T11:23:04Z
dc.date.issued2017-11
dc.identifier.citationEuropean journal of cancer (Oxford, England : 1990), 2017, 86 pp. 158 - 165
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/874
dc.identifier.eissn1879-0852
dc.identifier.doi10.1016/j.ejca.2017.09.005
dc.description.abstractAlthough biliary tract cancers (BTCs) are known to have an inflammatory component, a detailed characterisation of immune-related transcripts has never been performed. In these studies, nCounter PanCancer Immune Profiling Panel was used to assess the expression of 770 immune-related transcripts in the tumour tissues (TTs) and matched adjacent tissues (ATs) of resected BTCs. Cox regression analysis and Kaplan-Meier methods were used to correlate findings with relapse-free survival (RFS). The first analysis in the TT and AT of an exploratory set (n = 22) showed deregulation of 39 transcripts associated with T-cell activation. Risk of recurrence was associated with a greater number of genes deregulated in AT in comparison to TT. Analysis in the whole set (n = 53) showed a correlation between AT cytotoxic T-lymphocyte antigen-4 (CTLA4) expression and RFS, which maintained statistical significance at multivariate analysis. CTLA4 expression correlated with forkhead box P3 (FOXP3) expression, suggesting enrichment in T regulatory cells. CTLA4 is known to act by binding to the cluster of differentiation 80 (CD80). No association was seen between AT CD80 expression and RFS. However, CD80 expression differentiated prognosis in patients who received adjuvant chemotherapy. We showed that the immunomodulatory transcriptome is deregulated in resected BTCs. Our study includes a small number of patients and does not enable to draw definitive conclusions; however, it provides useful insights into potential transcripts that may deserve further investigation in larger cohorts of patients.Transcript profiling Nanostring data have been submitted to GEO repository: GSE90698 and GSE90699.
dc.formatPrint-Electronic
dc.format.extent158 - 165
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectLymphocytes, Tumor-Infiltrating
dc.subjectHumans
dc.subjectBiliary Tract Neoplasms
dc.subjectDisease-Free Survival
dc.subjectTreatment Outcome
dc.subjectBiliary Tract Surgical Procedures
dc.subjectMultivariate Analysis
dc.subjectProportional Hazards Models
dc.subjectRetrospective Studies
dc.subjectGene Expression Profiling
dc.subjectTumor Escape
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectTime Factors
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectItaly
dc.subjectFemale
dc.subjectMale
dc.subjectT-Lymphocytes, Regulatory
dc.subjectForkhead Transcription Factors
dc.subjectKaplan-Meier Estimate
dc.subjectTumor Microenvironment
dc.subjectCTLA-4 Antigen
dc.subjectTranscriptome
dc.subjectBiomarkers, Tumor
dc.subjectB7-1 Antigen
dc.titleCharacterisation of the immune-related transcriptome in resected biliary tract cancers.
dc.typeJournal Article
dcterms.dateAccepted2017-09-04
rioxxterms.versionofrecord10.1016/j.ejca.2017.09.005
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of cancer (Oxford, England : 1990)
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume86
pubs.embargo.termsNot known
icr.researchteamSignal Transduction & Molecular Pharmacologyen_US
icr.researchteamEvolutionary Genomics & Modellingen_US
icr.researchteamGastrointestinal Cancer Biology and Genomicsen_US
dc.contributor.icrauthorHahne, Jensen
dc.contributor.icrauthorBraconi, Chiaraen
dc.contributor.icrauthorCarotenuto, Pietroen
dc.contributor.icrauthorLampis, Andreaen
dc.contributor.icrauthorValeri, Nicolaen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0